Synthesis and evaluation of 2-(3′-lodo-4′-aminophenyl)-6-hydroxybenzothiazole for in vivo quantitation of amyloid deposits in alzheimer’s disease.

Autor: Wang, Yanming, Klunk, William, Huang, Guo-Feng, Debnath, Manik, Holt, Daniel, Mathis, Chester
Zdroj: Journal of Molecular Neuroscience; Aug2002, Vol. 19 Issue 1/2, p11-16, 6p
Abstrakt: A potent and brain permeable amyloid ligand has been identified as a lead compound capable of I-123/125-labelling for single photon emission computed tomography (SPECT) imaging. In this study, we report the synthesis and I-125-radiolabelling of Compound 6 and its in vitro and in vivo properties. Compound 6 [2-(3′-iodo-4′-aminophenyl)-6-hydroxybenzothiazole] bound to synthetic Aβ(1–40) fibrils in a saturable manner, exhibiting an affinity (Ki) of 11±1.1 nM in a competitive binding assay using a tritiated thioflavin T analog ([3H]BTA-1) as radioligand. [125I] 6 binding to synthetic Aβ(1–40) fibrils fit a single-site model. [125I] 6 exhibited several-fold higher binding to homogenates of frontal cortex from post-mortem Alzheimer’s disease brain relative to age-matched control brain homogenates. No difference in binding was observed in cerebellum. The ratio of radioactivity concentration between frontal cortex and cerebellum was 6-fold higher in AD brain homogenates than the age-matched control. [125I] 6 also readily penetrated the blood-brain barrier in normal control mice with an average radioactivity concentration of 6.43 ± 0.62%ID/g detected in the whole brain at 2 min post i.v. injection. At 30 min, the radioactivity concentration decreased to 0.40 ± 0.05%ID/g, indicating good clearance in the absence of amyloid deposits in the brain. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: